|
|
Article: Rib-X Brings In $50M Through Series C For Antibiotic Pipeline.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Rib-X Pharmaceuticals Inc. raised $50 million in its Series C round to fund development of its two clinical-stage antibiotics, including the first program to emerge from its drug discovery engine.
Money will be used to advance the company's Rx-01 program, which is in Phase I testing as both an oral and intravenous agent for hospital-acquired, Gram-positive infections. Rib-X also plans to begin its own clinical testing of WQ-3034, a Phase II-stage broad-spectrum quinolone antibiotic licensed earlier this month from Osaka, Japan-based Wakunaga Pharmaceutical Co. Ltd., said Susan Froshauer, president and CEO of New Haven, Conn.-based Rib-X.
...
Related newspaper, magazine, and journal articles:
|
|
Article: Crispy lamb spare ribs with honey creme fraiche and ...
Nation's Restaurant News;
October 20, 2003 ;
613 words
... ... Executive chef Victor LaPlaca has his supplier cut lamb ribs like pork spare ribs. He sears them and then braises them in red wine, veal stock, mirepoix and garlic. Then he cools the ribs overnight and the next day cuts them into individual ...
|
|